Huntsworth bolsters market access capabilities with Creativ-Ceutical
Health comms agency Huntsworth has strengthened its presence in health economics and market access services with the acquisition of Creativ-Ceutical.
The company says the buyout of Creativ-Ceutical (CC) will add strategic and technical capability and a global footprint to Huntsworth’s existing medical division MEDiSTRAVA.
The acquisition will create a division employing 340 experts across 18 offices across Europe, Africa, Asia, Oceania and North America.
“This is an exciting time for CC becoming part of Huntsworth Medical and forming an amazing group of 340 talented scientists in healthcare. Joining a professional, international top-ranking organisation will allow CC to reach the next development milestone – faster, smarter and smoother. Obvious synergies will expand our offering in terms of content and scope of work. The excellent cultural match between both parties is a strong predictor of success for the benefit of our employees and clients,” said Professor Mondher Toumi, MD, MSc, PhD, President and CEO Creativ-Ceutical.
The CC leadership team will work with its counterparts in MEDiSTRAVA including the medical agency ApotheCom and MEDiSTRAVA consulting to integrate across existing clients and new opportunities in early clinical development and life cycle planning.
The integration will include the creation of a single office in key locations, with a focus on expanding HEOR services in North America, where MEDiSTRAVA has strength and depth in medical affairs and operations on East and West coasts.
Elaine Ferguson, chief executive of MEDiSTRAVA said the enlarged company would provide clients with a fully integrated approach.
“We have admired the CC team for many years and together we provide fully aligned and complementary services across scientific strategy and communications, medical affairs, HEOR and market access with a unified strategic vision that focuses on meaningful outcomes and informed decision-making,”